spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  TYSABRI 

 HSMN NewsFeed - 17 Jul 2024
Alltrna Announces Updates to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jul 2019
Geron Enhances Oncology Expertise to Advance Corporate Objectives
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Apr 2019
Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2017
Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine(R) Foam
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 1 Mar 2017
Perrigo Announces FDA Final Approval For The Generic Version Of Axiron(R) Topical Solution, 30 mg/1.5 mL
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 17 Feb 2017
Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 24 Jan 2017
Perrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort(R) Spray, 0.25%
Biopharmaceuticals Generics Dermatology FDA
 HSMN NewsFeed - 23 Aug 2016
Perrigo Announces Tentative FDA Approval For Generic Version Of Suprep(R) Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso(R) Gel
Biopharmaceuticals Generics FDA Litigation
 HSMN NewsFeed - 21 Jun 2016
Perrigo Announces FDA Clearance And Launch Of Non-GMO* Infant Formulas For The U.S. Store Brand Market
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 2 May 2016
Perrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin(R) Pump Topical Gel
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 23 Mar 2016
Perrigo And Allergan Announce First-To-Market Launch Of Store Brand OTC Equivalent To Mucinex(R) 1200mg ER Tablets
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 10 Nov 2015
Perrigo Announces FDA Approval Of The AB Rated Generic Version Of KlorCon(R) Extended-Release Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 28 Aug 2015
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Sep 2014
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 29 Jan 2014
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 29 Jul 2013
Perrigo Company to Acquire Elan Corporation, plc for US$8.6 Billion, Establishing Premier Global Healthcare Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 May 2013
Elan Announces Transactions: Decisively Transforming the Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Apr 2013
Royalty Pharma Announces Firm Offer to Acquire Elan
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Feb 2013
Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 16 Jan 2013
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Aug 2012
Dyax Corp. Creates COO Position and Expands Executive Roles
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2012
VIVUS Announced Expansion of Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2012
Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2012
Quest Diagnostics STRATIFY JCV(TM) First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
Diagnostics Neurology Personalized Medicine FDA
 HSMN NewsFeed - 29 Sep 2011
Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Elan Announces Board of Director Changes
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Jan 2011
Anders Lundström to Be the New CEO of Orexo
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2010
Elan Names Robert A. Ingram Chairman-Designate
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2010
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Jan 2010
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2009
Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 14 Sep 2009
Elan Cures Breach of Tysabri(R) Collaboration Agreement and Amends Terms of Transaction with Johnson & Johnson
Biopharmaceuticals Litigation
 HSMN NewsFeed - 15 May 2009
Avila Therapeutics Appoints Katrine S. Bosley as Company's First CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Feb 2009
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2009
MS Patients Treated with TYSABRI Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Sep 2008
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 May 2008
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2008
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Jan 2008
MicroIslet Announces the Appointments of Dr. Chris Marsh as Lead Transplant Advisor, and Dr. Ronald Goldblum as Lead Clinical Development Consultant
Regenerative Medicine Personnel
 HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Biopharmaceuticals FDA Gastroenterology
 HSMN NewsFeed - 7 Jan 2008
Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Nov 2007
Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Oct 2007
New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Oct 2007
Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 15 Oct 2007
Elan Update
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2007
Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Aug 2007
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2007
Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 31 Jul 2007
OXiGENE Appoints Patricia Walicke, M.D., Ph.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Jul 2007
Biotechnology Start-up Nuon Therapeutics Inc. Completes $5 Million Series A Financing and Names Management Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 19 Jul 2007
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 18 Jun 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 May 2007
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
Biopharmacetuicals Gastroenterology FDA
 HSMN NewsFeed - 3 May 2007
Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jan 2007
Teva Receives Approval for Generic Focalin(TM) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 24 Jan 2007
Teva Files Patent Infringement Complaints Regarding Sertraline Hydrochloride
Biopharmaceuticals Litigation
 HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Dec 2006
Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 29 Nov 2006
Teva Announces Tentative Approval of Sumatriptan Succinate Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 21 Nov 2006
Teva Announces Agreement with Pfizer Regarding Idarubicin, Azithromycin, and Epirubicin
Biopharmaceuticals Litigation
 HSMN NewsFeed - 14 Nov 2006
Court of Appeals Affirms Teva's Generic Zocor(R) Exclusivity
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 24 Oct 2006
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Oct 2006
TEVA Announces Planned Retirement of President & CEO in 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2006
Teva Announces OxyContin(R) Litigation Dismissed; Settlement with Purdue Finalized
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 12 Oct 2006
Teva Announces Tentative Approval for Generic Risperdal(R) Oral Solution
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Oct 2006
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2006
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
New Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
Study Showed Significant and Sustained Efficacy Of COPAXONE(R) Alone Following Short-Term Combination Therapy With IV Steroids in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Sep 2006
Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. Announce a Collaboration Agreement for the Development of Two Biopharmaceuticals, Based on Protalix's Recombinant Plant Cell Expression Technology
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 Jul 2006
Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Jul 2006
Teva Announces Final Approval of Meloxicam Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 12 Jul 2006
Teva Announces Tentative Approval of Generic Lotrel(R) Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jun 2006
Teva Receives FDA Approval for Generic Zoloft(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 30 Jun 2006
OXiGENE'S Board of Directors Names Experienced Biotech Executive, Richard Chin, M.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2006
TYSABRI(R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 27 Jun 2006
Teva Provides Generic Biaxin(R) XL Update
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Jun 2006
Teva Receives First U.S. Approval of Generic Zocor(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 23 Jun 2006
Teva Announces Novartis' Sandoz Unit Seeks to Delay First FDA Approval of Generic Zocor(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 22 Jun 2006
Court of Appeals Rules in Favor of Teva on Biaxin(R) XL Preliminary Injunction
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 28 May 2006
Teva Announces Tentative Approval for Generic Cozaar(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 25 May 2006
Teva Announces Tentative Approval of Simvastatin Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 22 May 2006
Teva Announces Approval of Generic Lexapro(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 May 2006
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 May 2006
Teva Announces Approval of Polyethylene Glycol 3350 NF for Oral Solution
Biopharmaceuticals Generics FDA
Return to NewsFeed  

 Additional items found! 54

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 54 additional stories matching:
TYSABRI
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.